✨ Free AI Report
Curatis Holding AG: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Curatis Holding AG
Research Preview

Curatis Holding AG: Business Overview, Financials & Competitive Analysis

Curatis Holding AG is a Swiss specialty pharmaceutical company focused on acquiring, developing, and commercializing innovative medicines for rare and specialty care diseases. Founded in 2002 and listed on SIX Swiss E...

Analyst-debate audio for Curatis Holding AG

AskCyborg analysts argue the bull and bear cases for Curatis Holding AG across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Curatis Holding AG OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Rare disease focus with proven distribution revenue combined with clinical-stage assets offers asymmetric risk-reward, contingent...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals - Orphan/Rare Diseases
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Curatis Holding AG Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Curatis Holding AG Overview

Pro stress-test →

Curatis Holding AG is a Swiss specialty pharmaceutical company focused on acquiring, developing, and commercializing innovative medicines for rare and specialty care diseases. Founded in 2002 and listed on SIX Swiss Exchange since early 2024, Curatis operates through both a profitable distribution business for orphan drugs and a pipeline of proprietary drug candidates in clinical development.

Strategic Profile

Pro stress-test →

Curatis has differentiated itself as a leader in the Swiss orphan drug market with exclusive distribution rights for 40+ products and a growing presence planned across major European markets. The company combines immediate revenue generation from its distribution business with high-value development opportunities, particularly its Phase IIb lead candidate C-PTBE-01 for peritumoral brain edema. Recent financials show 30% distribution sales growth and a strategic pivot toward geographic and product portfolio expansion.

Competitive Landscape

Pro stress-test →

Curatis competes in the niche orphan drug space against larger pharmaceutical distributors and integrated biotech companies. Direct competitors include Recordati (orphan drugs division), Santhera Pharmaceuticals, and Actelion (acquired by J&J). Unlike larger competitors, Curatis maintains focused positioning in Switzerland with European expansion ambitions, competing through specialized expertise and direct relationships rather than scale.

Industry Context

Curatis Holding AG operates in Specialty Pharmaceuticals - Orphan/Rare Diseases.

Key facts

Founded: 2002 · Headquarters: Liestal, Switzerland · Employees: ~8 · Revenue: CHF 6.9M (2024, 8-month post-acquisition) · Market cap: CHF 58.16M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Curatis Holding AG.

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Curatis Holding AG has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Orphan Drug DistributionLarge-cap pharmaceutical company with extensive orphan drug portfolio across Europe→Rare Disease DevelopmentSwiss biotech focused on neuromuscular and respiratory rare diseases→Rare Disease FocusSwiss-origin, major pharma-backed rare disease and pulmonary hypertension franchise→

Compare Curatis Holding AG with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Curatis Holding AG operates in Specialty Pharmaceuticals - Orphan/Rare Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Pharmaceuticals - Orphan/Rare Diseases research →
NEW · MCP server

Ask your AI assistant about Curatis Holding AG

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Curatis Holding AG and its top competitor on Cyborg Score”
“What did Curatis Holding AG do this quarter?”
“Is Curatis Holding AG a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Curatis Holding AG do?+
Curatis Holding AG is a Swiss specialty pharmaceutical company focused on acquiring, developing, and commercializing innovative medicines for rare and specialty care diseases. Founded in 2002 and listed on SIX Swiss E...
What is Curatis Holding AG's Cyborg Score?+
Curatis Holding AG has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Curatis Holding AG's main competitors?+
Named competitors include Orphan Drug Distribution, Rare Disease Development, Rare Disease Focus. The full competitive landscape is in the AskCyborg report.
How can I get the full Curatis Holding AG research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Curatis Holding AG research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Curatis Holding AG over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.